免疫系统
炎症
免疫学
炎症性肠病
生物
NF-κB
先天免疫系统
获得性免疫系统
信号转导
胃肠道
转录因子
促炎细胞因子
平衡
疾病
细胞生物学
医学
遗传学
病理
基因
生物化学
作者
Tapas Mukherjee,Naveen Kumar,M. L. Chawla,Dana J. Philpott,Soumen Basak
出处
期刊:Science Signaling
[American Association for the Advancement of Science]
日期:2024-01-09
卷期号:17 (818)
被引量:28
标识
DOI:10.1126/scisignal.adh1641
摘要
Inflammatory bowel disease (IBD) is an idiopathic, chronic condition characterized by episodes of inflammation in the gastrointestinal tract. The nuclear factor κB (NF-κB) system describes a family of dimeric transcription factors. Canonical NF-κB signaling is stimulated by and enhances inflammation, whereas noncanonical NF-κB signaling contributes to immune organogenesis. Dysregulation of NF-κB factors drives various inflammatory pathologies, including IBD. Signals from many immune sensors activate NF-κB subunits in the intestine, which maintain an equilibrium between local microbiota and host responses. Genetic association studies of patients with IBD and preclinical mouse models confirm the importance of the NF-κB system in host defense in the gut. Other studies have investigated the roles of these factors in intestinal barrier function and in inflammatory gut pathologies associated with IBD. NF-κB signaling modulates innate and adaptive immune responses and the production of immunoregulatory proteins, anti-inflammatory cytokines, antimicrobial peptides, and other tolerogenic factors in the intestine. Furthermore, genetic studies have revealed critical cell type–specific roles for NF-κB proteins in intestinal immune homeostasis, inflammation, and restitution that contribute to the etiopathology of IBD-associated manifestations. Here, we summarize our knowledge of the roles of these NF-κB pathways, which are activated in different intestinal cell types by specific ligands, and their cross-talk, in fueling aberrant intestinal inflammation. We argue that an in-depth understanding of aberrant immune signaling mechanisms may hold the key to identifying predictive or prognostic biomarkers and developing better therapeutics against inflammatory gut pathologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI